Jean‐Jacques Grob
0000-0002-0667-153X
Publication & Citation Trends
Publications
0 total
Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727]
Cited by 0
Semantic Scholar
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma OA
Cited by 0
Semantic Scholar
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
Cited by 26
Semantic Scholar
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
Cited by 2
Semantic Scholar
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Cited by 0
Semantic Scholar
Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Cited by 0
Semantic Scholar
Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma OA
Cited by 0
Semantic Scholar
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Cited by 2
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(241)
Melanoma and MAPK Pathways
(227)
CAR-T cell therapy research
(214)
Cutaneous Melanoma Detection and Management
(203)
Nonmelanoma Skin Cancer Studies
(88)
Affiliations
Université Claude Bernard Lyon 1
Uppsala University
Novartis (Switzerland)
Centre National de la Recherche Scientifique
Université de Bordeaux